ITMCTR2200006369
Recruiting
未知
A multicenter, double-blinded, randomized, parallel group and placebo-controlled clinical study of the efficacy and safety of Fuzheng Jiedu granules in the treatment of COVID-19
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Traditional Chinese Medicine)0 sitesTBD
ConditionsCOVID-19
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Traditional Chinese Medicine)
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects must meet all of the following criteria:
- •1\. SARS\-CoV\-2 positive;
- •2\. Aged between 18 and 85 (including 18 and 85\)
- •3\. At the time of entry, the subject has at least one of the following clinical symptoms with a symptom score \=1, including but not limited to: fever, cough, sore throat, stuffy or runny nose, headache, muscle pain, nausea, vomiting, diarrhea, shortness of breath or dyspnea, chills;
- •4\. Subjects shall meet at least one of the following requirements: 1\) The time between the samples tested positive for SARS\-COV\-2 and the first using of test drug is no more than 3 days; 2\) \=3 days from the first onset of COVID\-19 symptoms to the first administration of the investigational drug;
- •5\. The TCM syndrome differentiation in screening period was divided into Yang deficiency and wet toxin not clear; Symptoms: pale complexion, fear of cold, cold limbs, fatigue, chest tightness, shortness of breath, nausea, poor stomach intake, thin stools, pale and dark tongue, yellow and greasy or white and greasy coating, weak or heavy pulse.
- •6\. Informed consent signed by the subject or his/her legal representative.
Exclusion Criteria
- •Subjects with one of the following conditions will be excluded:
- •1\. Subjects have received antiviral therapy before entry, such as Paxlovid, ritonavir, and SARS\-COV\-2 monoclonal antibody therapy (excluding previous treatment for COVID\-19\);
- •2\. Subjects have received convalescent plasma from convalescent patients and other clinical trial drugs for COVID\-19 indication before entering the study (excluding previous treatment for COVID\-19\);
- •3\. Subjects have been treated with proprietary Chinese medicine or Chinese medicine prescription before entering the study (excluding previous treatment of COVID\-19\);
- •4\. Suspected bacterial, fungal, viral or other infections other than the Novel Coronavirus during the screening period;
- •5\. Subjects had bronchopneumonia, chronic lung abscess, chronic cough for more than 8 weeks, chronic pharyngitis with cough and other diseases before entering the study;
- •6\. Mechanical ventilation is required or is expected to be urgently required;
- •7\. In the investigator's judgment, the subject is in a death crisis or death is inevitable within the next 24 hours, regardless of treatment;
- •8\. During the screening period, one of the following conditions occurs: 1\) ALT or AST\> 1\.5x ULN; 2\) eGFR \< 60 ml/min. 3\) Hemoglobin \<8\.0g/L, platelet \<5000/uL;
- •9\. Used other investigational drugs 30 days prior to baseline visit or during the drug's five half\-lives (whichever is longer), or planned to use the drug during the study;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
HIPER-500KCT0002734Samsung Medical Center120
Active, not recruiting
Not Applicable
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 17.0Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Body processes [G] - Biological Phenomena [G16]EUCTR2010-021871-10-ATInnovacell Biotechnologie AG - Life Science Center Innsbruck372
Active, not recruiting
Not Applicable
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 14.1Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Body processes [G] - Biological Phenomena [G16]EUCTR2010-021871-10-BGInnovacell Biotechnologie AG - Life Science Center Innsbruck372
Active, not recruiting
Not Applicable
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 17.1Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Body processes [G] - Biological Phenomena [G16]EUCTR2010-021871-10-DEInnovacell Biotechnologie AG - Life Science Center Innsbruck372
Active, not recruiting
Not Applicable
The aim of this clinical study is to show efficacy and safety of cells in patients suffering from stress urinary incontinence and to show superiority of cells in female patients with stress urinary incontinence over placebo.Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patientsMedDRA version: 18.0Level: PTClassification code 10066218Term: Stress urinary incontinenceSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Body processes [G] - Biological Phenomena [G16]EUCTR2010-021871-10-CZInnovacell Biotechnologie AG - Life Science Center Innsbruck369